Probatebeta
Target

PDGFRA

Platelet-derived growth factor receptor alpha

As of the edition of 20 October 2026, PDGFRA (platelet-derived growth factor receptor alpha, UniProt P16234) has 32 drugs tested at it and 35 companies on the list, 15 on route A and 7 on route B.

Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.

The protein

UniProt
P16234
How well studied
Drug target: an approved drug acts on it
Where it sits in the cell
In more than one place
Solved structures
18
Disease areas
Cancer; Digestive system; Urinary and reproductive; Pregnancy and women's health; Lungs and airways; Blood and lymph; Skin and connective tissue; Hormones
Registered trials of its drugs
1,640

Drugs at this target

StatusCount
Marketed10
Active4
Went quiet7
Stopped10
Status not established1
Total32
DrugStatusFurthest phaseUS protection
SunitinibMarketedPhase 4none listed
RegorafenibMarketedPhase 4Ends 2032
PazopanibMarketedPhase 4none listed
NintedanibMarketedPhase 4Ends 2027
CediranibStoppedPhase 3none listed
FamitinibStoppedPhase 3none listed
DovitinibActivePhase 3none listed
MidostaurinMarketedPhase 3none listed
QuizartinibMarketedPhase 3Ends 2030
MasitinibStoppedPhase 3none listed
VatalanibWent quietPhase 3none listed
AvapritinibMarketedPhase 4Ends 2040

12 of 32 drugs, the most tested first.

Companies at this target

Where the company standsCompanies
Route A15
Route B7
Engaged9
Undetermined4
Total on the list35
Three companies on route A or B, with the route only
CompanyRoute
PfizerRoute B
AstraZenecaRoute A
Boehringer IngelheimRoute B

The other 32 companies at PDGFRA

In the product

35 companies in all; 32 are not named here, and no score is.

See the 35 companies at PDGFRA, ranked, with the facts behind eachRequest access. Nothing is shown until you do.

More drugs at PDGFRA

Other targets in cancer

Companies holding approvals at PDGFRA